Form 4: Tempest Therapeutics CFO Acquires Stock Options

Tempest Therapeutics' Chief Financial Officer, Nicholas Maestas, was granted employee stock options for 140,000 shares.

Summary

• Nicholas Maestas, Chief Financial Officer of Tempest Therapeutics, Inc., was granted employee stock options.
• The options are for 140,000 shares of common stock with an exercise price of $1.64 per share.
• The earliest transaction date is March 31, 2026, with an expiration date of March 30, 2036.
• Vesting begins on March 31, 2027, with 25% of the shares vesting on that date, and the remainder vesting in 36 equal monthly installments thereafter, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard executive compensation event rather than a significant financial or strategic development for the company.

Positives

• Grant of stock options to a key executive, indicating potential alignment of management interests with shareholder value.
• The options provide a long-term incentive, with a vesting schedule tied to continued employment.

Risks

• The vesting of the options is subject to the Reporting Person's continued service, meaning any departure before full vesting would result in forfeiture of unvested options.
• The value of the options is directly tied to the future performance and stock price of Tempest Therapeutics.

Future Outlook

The stock options are exercisable at $1.64 and vest over time, suggesting a long-term outlook for the executive's commitment and potential future stock performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to a Chief Financial Officer is a standard practice in the biotechnology and pharmaceutical sectors to attract and retain executive talent and align their financial interests with the company's long-term success.

Stakeholder Impact

• Shareholders: The grant of options can be viewed positively as it aligns executive incentives with long-term shareholder value creation, but it also represents potential future dilution if options are exercised.

Next Steps

• Continued service by Nicholas Maestas to meet vesting requirements for the stock options.
• Potential exercise of vested stock options by Nicholas Maestas in the future, subject to market conditions and company performance.

Key Dates

Keywords

stock options, executive compensation, Tempest Therapeutics, TPST, Nicholas Maestas, CFO, insider trading, Form 4